# A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure

> **NCT03082508** · NA · UNKNOWN · sponsor: **LoneStar Heart, Inc.** · enrollment: 240 (estimated)

## Conditions studied

- Heart Failure
- Dilated Cardiomyopathy
- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DEVICE:** Algisyl
- **DRUG:** Standard Medical Therapy

## Key facts

- **NCT ID:** NCT03082508
- **Lead sponsor:** LoneStar Heart, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08
- **Primary completion:** 2020-01
- **Final completion:** 2024-01
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2017-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03082508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03082508, "A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03082508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*